News
Press Releases
2019/11/18
WuXi AppTec's Lab Testing Division Expands Toxicology Facility in Suzhou, China
SHANGHAI, Nov. 18, 2019 - WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced its Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80% to meet global customers’ preclinical testing needs and enable them to accelerate the development timelines and bring innovative medicines to patients faster.
Read more2019/11/15
WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan
SHANGHAI, Nov. 15, 2019 -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm. WuXi AppTec was awarded this honor for the third consecutive year.
Read more2019/11/11
Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019
SHANGHAI, November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced today that its Chairman and CEO Dr. Ge Li was awarded “CEO of the Year” at the CPhI Worldwide 2019, a top pharmaceutical event uniting over 45,000 professionals worldwide.
Read more2019/11/06
WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies
SHANGHAI, November 6, 2019: WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec.
Read more2019/10/30
WuXi AppTec Reports Third-Quarter 2019 Results
SHANGHAI, Oct. 30, 2019 -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its financial results for the third quarter and nine months ended September 30, 2019 ("Reporting Period").
Read more